Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study

https://doi.org/10.1016/j.jmgm.2021.107904Get rights and content

Highlights

  • A database containing 2017 flavone analogs was prepared and screened against SARS-CoV-2 Mpro using in silico techniques.

  • PubChem-129-716-607 and PubChem-885-071-27 demonstrated higher binding affinities against Mpro than rutin and baicalein.

  • PubChem-129-716-607 and PubChem-885-071-27 exhibited high stability inside the Mpro active site over 150 ns MD simulations.

  • PubChem-129-716-607 and PubChem-885-071-27 manifested promising drug-likeness properties.

Abstract

Coronavirus disease 2019 (COVID-19) is a new pandemic characterized by quick spreading and illness of the respiratory system. To date, there is no specific therapy for Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). Flavonoids, especially rutin, have attracted considerable interest as a prospective SARS-CoV-2 main protease (Mpro) inhibitor. In this study, a database containing 2017 flavone analogs was prepared and screened against SARS-CoV-2 Mpro using the molecular docking technique. According to the results, 371 flavone analogs exhibited good potency towards Mpro with docking scores less than −9.0 kcal/mol. Molecular dynamics (MD) simulations, followed by molecular mechanics-generalized Born surface area (MM/GBSA) binding energy calculations, were performed for the top potent analogs in complex with Mpro. Compared to rutin, PubChem-129-716-607 and PubChem-885-071-27 showed better binding affinities against SARS-CoV-2 Mpro over 150 ns MD course with ΔGbinding values of −69.0 and −68.1 kcal/mol, respectively. Structural and energetic analyses demonstrated high stability of the identified analogs inside the SARS-CoV-2 Mpro active site over 150 ns MD simulations. The oral bioavailabilities of probable SARS-CoV-2 Mpro inhibitors were underpinned using drug-likeness parameters. A comparison of the binding affinities demonstrated that the MM/GBSA binding energies of the identified flavone analogs were approximately three and two times less than those of lopinavir and baicalein, respectively. In conclusion, PubChem-129-716-607 and PubChem-885-071-27 are promising anti-COVID-19 drug candidates that warrant further clinical investigations.

Keywords

SARS-CoV-2 main protease
COVID-19
Molecular docking
Drug-likeness
Molecular dynamics

Cited by (0)

View Abstract